NEW YORK (360Dx) – Roche on Friday said that its PD-L1 assay has received CE-label expansion to identify untreated and previously treated patients with metastatic non-small cell lung cancer that are eligible for Merck's Keytruda (pembrolizumab) immunotherapy.

As a result, the Ventana PD-L1 (SP263) Assay — the only fully automated PD-L1 test for use with Keytruda to launch on Roche's BenchMark series of instruments — is available in countries accepting the CE mark, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.